• On November 17, 2025, Lunit and Labcorp announced a collaboration to advance digital pathology and artificial intelligence in oncology research and clinical care, with early results presented at major scientific conferences spotlighting the identification of immune-active subtypes in non-small cell lung cancer tumors.
• This initiative merges Labcorp’s clinical strengths with Lunit’s AI algorithms to enhance tumor microenvironment analysis, potentially improving precision in immuno-oncology strategies and biomarker discovery.
• We’ll examine how Labcorp’s integration of AI-powered pathology tools strengthens its efforts to drive innovation and efficiency in oncology services.

Find companies with promising cash flow potential yet trading below their fair value.

Labcorp Holdings Investment Narrative Recap

To be a shareholder in Labcorp Holdings, you need to believe in the company’s ability to drive growth through healthcare innovation, particularly in diagnostics and specialty testing. The newly announced partnership with Lunit to advance digital pathology in oncology represents a forward step, but it does not materially change the near-term catalysts or address the most immediate risks, such as potential regulatory headwinds or competitive pressures in diagnostics.

Among Labcorp’s recent updates, its ongoing introduction of new diagnostics, like the Elecsys pTau181 test for Alzheimer’s disease, is most relevant, as it signals the company’s push to grow through innovation and advanced testing, an approach mirrored in the AI-focused Lunit alliance. These efforts continue to support the core catalyst of increasing specialized test volume.

However, investors should also be aware that if regulatory or reimbursement changes occur quickly, especially around lab test pricing...

Labcorp Holdings' narrative projects $15.6 billion in revenue and $1.3 billion in earnings by 2028. This requires 5.1% yearly revenue growth and a $536.6 million earnings increase from $763.4 million today.

Uncover how Labcorp Holdings' forecasts yield a $300.12 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members offered four distinct fair value opinions for Labcorp ranging from US$200 to US$323.64 per share. While some see substantial upside, others remain cautious amid industry risks like cost pressures and regulatory changes, which could affect future earnings and margins.

Explore 4 other fair value estimates on Labcorp Holdings - why the stock might be worth 23% less than the current price!

Build Your Own Labcorp Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Labcorp Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Labcorp Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Labcorp Holdings' overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.